Opinion

Video

The Logistical Challenges in ccRCC Treatment

Panelists discuss how the logistical challenge of the new test requiring separate appointments (tracer injection followed by imaging 5 days later) is offset by scheduling flexibility because of the tracer’s 78-hour half-life and the technology essentially providing a “virtual biopsy” without invasive procedures.

Practical Considerations for Implementation

Main Discussion Topics:

  • Logistical challenges requiring separate appointments for tracer administration and imaging
  • Imaging window is 5 days (± 2 days) after tracer injection.
  • Long half-life (78 hours) provides flexibility in scheduling
  • Comparison with prostate-specific membrane antigen tracers, which require same-day imaging.

Key Points for Physicians:

  • Requires 2 separate patient visits: one for tracer injection, another for imaging.
  • A 5-day interval between injection and imaging (with 2-day flexibility)
  • A 96-hour shelf life provides scheduling flexibility.
  • Noninvasive approach compared with biopsy with comparable diagnostic performance

Notable Insights:

Despite logistical considerations requiring 2 visits, the experts view this as a “virtual biopsy,” with performance characteristics similar to actual tissue sampling but without invasiveness.

Clinical Significance:

The logistical requirements are outweighed by the potential clinical value and noninvasive nature of the test compared with biopsy alternatives.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
1 expert is featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.